Our experienced team provides consultancy services in relation to development of pharmaceutical and biotechnology products and medical devices: product R&D strategy, planning and execution; product manufacturer selection; pre-clinical study design and placement; clinical product development; regulatory strategy; clinical expert reports and overviews; scientific advice, orphan drug and paediatric plans; clinical trial applications; protocols and investigator’s brochures; MAA/NDA/BLA applications, lifecycle management; product commercialisation, clinical support activities; and due diligence evaluations. We are a cost-effective solution for those requiring assistance in order to expedite development and add value to your product, whether it relates to a single issue or a long term commitment.
Watch our Member Showcase video here https://bit.ly/3Gs0d87
Watch our Member Showcase video here https://bit.ly/3Gs0d87
Bridge Partners is an information and communications technology (ICT) support services company. Bridge Partners specialises in helping organisations to get the best from their information and communications technology. If you are starting from scratch, we can advise you on what to buy to support your business objectives. Where you have already made an investment in ICT, we will show you how to use it for maximum business benefit. We also offer strategic ICT advice to larger firms, helping them manage their technology resources and prepare their organisations and culture for change as well as providing connectivity and cloud services.. . We also offer strategic ICT advice to larger firms, helping them manage their technology resources and prepare their organisations and culture for change.
Bristows works with leading clients from across the sectors and offers a true spectrum of legal expertise, both contentious and non-contentious. The range of our experience enables us to advise on everything from the precedent-setting to the purely procedural. The common thread in everything we do is our ability to combine both commercial and legal perspectives. For more than 170 years, the Bristows name has represented a rigorous intellectual approach to the law, as well as a practical understanding of the ever-changing demands of business.
Broken String Bioscience’s technology platform, INDUCE-seq™ , supports the development of cell and gene therapies that are safer by design. INDUCE-seq™, is an NGS-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. The platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs.
No data available
No data available
No data available
Cambridge Employment Law LLP is a boutique employment law practice, advising both employers and employees. Our size and the specialist nature of our practice mean that you will have a personal relationship with a lawyer who understands your business and cares about its success. Our advice is always commercial and pragmatic, based on our lawyers' many years of experience and technical expertise. Eleanor Freeman has a particular interest in the biomedical sector. Her familiarity with the common challenges facing start-ups and high growth companies is balanced with significant experience representing global pharmaceuticals in all employment-related matters.
Cambridge Enterprise is responsible for the commercialisation of intellectual property from the University of Cambridge. We work with members of the university to help them commercialise their research and provide consultancy services to the industry. We give vital support to early-stage companies, helping them develop innovative technology ventures which benefit society and the wider economy.
Cambridge Innovation Capital (“CIC”) combines a unique relationship with the University of Cambridge and deep financial and industry links. CIC invests in rapidly growing intellectual property rich companies in the Cambridge Cluster. . . The company is committed to building leading businesses from brilliant technologies - with the support of some of the most influential figures in the sector and a patient capital structure.